Trevi Therapeutics upgraded by Raymond James with a new price target
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James upgraded Trevi Therapeutics from Outperform to Strong Buy and set a new price target of $29.00 from $9.00 previously